Identification of mutations in the HVR1 and PKR-BD regions in HCV-infected patients resistant to PEG-IFNα/RBV therapy
Tóm tắt
The identification of mutations in the HVR1 region of hepatitis type C virus (HCV) is time-consuming and expensive, and there is a need for a rapid, inexpensive method of screening for these mutations to predict the ineffectiveness of pegylated interferon alpha combined with ribavirin (PEG-IFNα/RBV) therapy. The project was designed to evaluate the usefulness of the high resolution melting (HRM) technique to screen for mutation in the cDNAs encoding the HVR1 and protein kinase R-binding domain (PKR-BD) regions in a group of 36 patients infected with HCV and resistant to 12 months of combined therapy with PEG-IFNα/RBV. Viral RNA was isolated, reverse transcribed, and the fragments encoding the HVR1 and PKR-BD regions were polymerase chain reaction (PCR)-amplified, cloned, sequenced, and the melting profiles and the melting temperature (Tm) were determined by the HRM technique. After the treatment, the melting profiles of HVR1 cDNAs revealed a dominant peak corresponding to the Tm of about 85 °C (HCVs85) in almost all patients. One or more minor peaks were also observed, indicating the existence of cDNA(s) of different Tm. The HMR analysis suggested four typical forms of response to treatment. These suppositions were supported by sequencing. The HRM analysis revealed no changes in the melting profiles of PKR-BD cDNAs in the same patient before and after the therapy, suggesting that, within 12 months of treatment, new mutations were not introduced in PKR-BD. These findings were substantiated by sequencing. The HRM technique can be applied for the rapid screening for mutations in the cDNAs encoding the HVR and PKR-BD regions of HCV. We suggest that the detection of HCVs85 peak before the IFNα/RBV therapy might predict the ineffectiveness of treatment.
Tài liệu tham khảo
Abdelrahman T, Hughes J, Main J, McLauchlan J, Thursz M, Thomson E (2015) Next-generation sequencing sheds light on the natural history of hepatitis C infection in patients who fail treatment. Hepatology 61:88–97. doi:10.1002/hep.27192
Aslan N, Bozdayi AM, Cetinkaya H, Sarioğlu M, Türkay C, Bozkaya H, Karayalçin S, Yurtaydin C, Uzunalimoğlu O (2004) The mutations in ISDR of NS5A gene are not associated with response to interferon treatment in Turkish patients with chronic hepatitis C virus genotype 1b infection. Turk J Gastroenterol 15:21–26
Berg T, Mas Marques A, Höhne M, Wiedenmann B, Hopf U, Schreier E (2000) Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology 32:1386–1395
Brojer E, Gloskowska-Moraczewska Z, Kacperska E, Medyńska J, Cianciara J, Juszczyk J, Loch T, Flieger J, Seyfried H (1996) Hepatitis C virus genotypes in blood donors and patients with chronic hepatitis C. Vox Sang 71:51–54
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction. Anal Biochem 162:156–159
Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, Ogura Y, Izumi N, Marumo F, Sato C (1996) Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 334:77–81
Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347:975–982
He Y, Tan SL, Tareen SU, Vijaysri S, Langland JO, Jacobs BL, Katze MG (2001) Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol 75:5090–5098
Holland JJ, De La Torre JC, Steinhauer DA (1992) RNA virus populations as quasispecies. Curr Top Microbiol Immunol 176:1–20
Holysz M, Bialas K, Migdalski P, Kmieciak D, Trzeciak WH (2014) Application of a high-resolution melting technique for the rapid detection of partial replacement of HCV-1b by HCV-1a after PEG-IFNα/RBV therapy. J Appl Genet. doi:10.1007/s13353-014-0256-3
Kmieciak D (2005) The mechanisms of hepatitis C virus resistance to interferon. Postepy Biochem 51:22–27
Kmieciak D, Kruszyna Ł, Migdalski P, Łaciński M, Juszczyk J, Trzeciak WH (2006) Mutations within protein kinase R-binding domain of NS5A protein of hepatitis C virus (HCV) and specificity of HCV antibodies in pretreatment sera of HCV-chronically infected patients and their effect on the result of treatment. Jpn J Infect Dis 59:92–99
Kmieciak D, Migdalski P, Juszczyk J, Jagodziński PP, Trzeciak WH (2009) Identification of a hepatitis C virus mutant lacking the hypervariable region 1 in a chronically infected patient non-responding to PEG-interferon-alpha/ribavirin therapy. Eur J Clin Microbiol Infect Dis 28:211–213
Kozielewicz D, Halota W, Dybowska D (2012) Efficacy of triple therapy in patients with chronic hepatitis C not treated and patients previously treated ineffectively. Przegl Epidemiol 66(1):49–54
Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358:958–965
Nousbaum J, Polyak SJ, Ray SC, Sullivan DG, Larson AM, Carithers RL Jr, Gretch DR (2000) Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 74:9028–9038
Simmonds P (2004) Genetic diversity and evolution of hepatitis C virus—15 years on. J Gen Virol 85:3173–3188
World Health Organization (WHO) (2014) Guidelines for the screening, care and treatment of persons with hepatitis C infection. WHO, April 2014. Available online at: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/